Biotie being courted by potential partners for Alzheimer’s drugBloomberg Businessweek20 February 2012-----------Panu Miettinen appointed chief financial officer of BiotieInPharm16 February 2012------------Lundbeck seeks approval for a novel alcoholism treatmentPharma and Healthcare Insight30 December 2011-------------Biotie tests cocaine dependence treatment in USAPharma Times14 December 2011-------------Scandinavian biotech hit particularly hard in bad year for sectorEPVantage from EvaluatePharma2 December 2011--------------Biotie pulls out of merger with Newron Pharma Times28 October 2011--------------Biotie initiates SYN120 Phase 1 study using PET imagingMedical Devices Business Review25 July 2011--------------Lundbeck to file alcoholism pill this yearInPharm16 June 2011--------------Lundbeck to file alcoholism drug in Europe by year endPharma Times16 June 2011--------------Lundbeck finishes alcohol dependency trialsPMLiVE15 June 2011--------------Lundbeck nails PhIII for drug to curb alcohol dependenceFierceBiotech15 June 2011--------------Nalmefene reaches Phase III endpoints
European Biotechnology News6 February 2011--------------Biotie to acquire CNS therapeutics firm Synosia in €93.6M all-shares dealGenetic Engineering & Biotechnology News11 January 2011--------------Biotie buys CNS developer Synosia in $121.5M dealFierceBiotech11 January 2011--------------Alcoholics may stop at one drink with help from Lundbeck anti-abuse drugBloomberg23 December 2010 --------------------------------Updated February 21, 2012